Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer

被引：0

作者：

Susanne Taucher

Margaretha Rudas

Robert M. Mader

Michael Gnant

Emanuel Sporn

Peter Dubsky

Sebastian Roka

Thomas Bachleitner

Florian Fitzal

Daniela Kandioler

Catharina Wenzel

Günther G. Steger

Martina Mittlböck

Raimund Jakesz

机构：

[1] Vienna University Medical School,Department of Surgery

[2] Vienna University Medical School,Department of Pathology

[3] Vienna University Medical School,undefined

来源：

Breast Cancer Research and Treatment | 2003年 / 82卷

关键词：

breast cancer; core needle biopsy; docetaxel; epirubicin; FISH; HER2/; immunohistochemistry; preoperative treatment; trastuzumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background. In primary breast cancer, the expression levels of biological markers relevant to the progression of the disease may be altered by administration of anticancer drugs. Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu.

引用

页码：207 / 213

页数：6

共 50 条

[11] Her2/neu expression in relation to clinicopathological features of breast cancer patients
Traina, Adele
Agostara, Biagio
Marasa, Lorenzo
Adamo, Stella
Amodio, Rosalba
Dolcemascolo, Cecilia
Zarcone, Maurizio
Carruba, Giuseppe
ANNALS OF ONCOLOGY, 2007, 18 : 39 - 40
[12] HER2/neu expression in relation to clinicopathologic features of breast cancer patients
Traina, Adele
Agostara, Biagio
Marasa, Lorenzo
Calabro, Maurizio
Zarcone, Maurizio
Carruba, Giuseppe
ESTROGENS AND HUMAN DISEASES, 2006, 1089 : 159 - 167
[13] β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis
Drebber, Uta
Madeja, Martin
Odenthal, Margarete
Wedemeyer, Inga
Moenig, Stefan P.
Brabender, Jan
Bollschweiler, Elfriede
Hoelscher, Arnulf H.
Schneider, Paul M.
Dienes, Hans P.
Vallboehmer, Daniel
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (09) : 1127 - 1134
[14] β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis
Uta Drebber
Martin Madeja
Margarete Odenthal
Inga Wedemeyer
Stefan P. Mönig
Jan Brabender
Elfriede Bollschweiler
Arnulf H. Hölscher
Paul M. Schneider
Hans P. Dienes
Daniel Vallböhmer
International Journal of Colorectal Disease, 2011, 26
[15] Ethnic differences in expression of steroid receptors and HER2/neu in breast cancer patients
Malyshev, Nikolay
Perminov, Vladimir
Uysin, Asel
Kulishov, Vladimir
Sirota, Valentina
ANNALS OF ONCOLOGY, 2007, 18 : 165 - 165
[16] Decreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer
Mogica, Jan Paredes
Tang, Haiming
Fischbach, Neal A.
Zhan, Haiying
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[17] HER2/neu vaccines in breast cancer
Khoo, Steven
Ponniah, Sathibalan
Peoples, George E.
WOMENS HEALTH, 2006, 2 (02) : 217 - 223
[18] Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene
Harbeck, Nadia
Pegram, Mark D.
Rueschoff, Josef
Moebus, Volker
BREAST CARE, 2010, 5 : 3 - 7
[19] EVALUATION OF HER2/NEU EXPRESSION IN BREAST CANCER BONE METASTASES
Juan Illarramendi, Jose
Cordoba, Alicia
Fernandez Seara, Pilar
Lopez Cousillas, Alfredo
Amat, Irene
Reparaz, Begona
Ruiz De Azua, Geranie
De Miguel, Concepcion
Salgado, Esteban
Vera, Ruth
Munoa, Javier
BREAST, 2011, 20 : S28 - S28
[20] Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial
Zhu, L
Chow, LWC
Loo, WTY
Guan, XY
Toi, M
CLINICAL CANCER RESEARCH, 2004, 10 (14) : 4639 - 4644

← 1 2 3 4 5 →